NeuroPace Director’s Quiet 865‑Share Buy Signals Confidence Amid Price Volatility

Insider Buying Continues Amid Volatile Market Conditions NeuroPace Inc. (NASDAQ: NPSP) has seen a modest yet notable uptick in insider buying from one of its senior non‑employee directors, Lacob Joseph, on March 20, 2026. The transaction involved the purchase of 865 shares at $13.00 each—just below the close of $13.38—bringing Joseph’s holdings to 14,754 shares. While the number of shares is relatively small compared with the company’s total outstanding shares, the purchase is part of a broader pattern of disciplined, low‑risk accumulation that has characterized Joseph’s insider activity over the past 18 months.

What the Latest Deal Signals for Investors The timing of the buy is particularly interesting given NeuroPace’s recent quarterly performance, which has seen a 3.98% decline in the last week and an 8.86% drop over the month. The company’s price‑earnings ratio remains negative at –20.276, underscoring ongoing profitability challenges. In this environment, any insider purchase can be interpreted as a vote of confidence. Investors should note, however, that the trade is linked to a non‑employee director compensation policy rather than a direct market purchase, suggesting that the transaction is more about aligning executive interests with shareholders than about capitalizing on a price dip.

Lacob Joseph: A Profile of Cautious Accumulation Lacob Joseph has steadily increased his stake in NeuroPace through a series of small buy‑orders and stock‑option exercises. His historic transactions reveal a pattern of purchasing between 678 and 1,131 shares at prices ranging from $9.94 to $16.59, often coinciding with periods of price volatility. Unlike some insiders who liquidate positions during downturns, Joseph has consistently added to his holdings, even exercising options at no cost in June 2025. His cumulative ownership now exceeds 14,000 shares, and his holdings are held directly (not through holding companies), reflecting a personal commitment to the company’s long‑term prospects.

Insider Activity Across the Board NeuroPace’s insider activity is not limited to Joseph. Recent Form 4 filings also show significant purchases by other directors—Kumar Rakhi and Frank Fischer—though these are largely compensation grants rather than market trades. On the other hand, key executives such as CEO Joel Becker and CMOs Martha Morrell have been selling shares, raising concerns about potential insider concerns over the company’s near‑term outlook. The contrast between the buying by non‑employee directors and selling by senior executives creates a nuanced picture that investors must parse carefully.

Strategic Implications for the Company’s Future If the trend of low‑volume, low‑price insider buying continues, it could signal a belief that NeuroPace’s valuation will recover as its therapeutic pipeline matures. The company’s flagship responsive neurostimulation system has already received FDA clearance, and ongoing clinical data could unlock additional revenue streams. However, the negative earnings ratio and recent price decline suggest that the market remains cautious. Investors should weigh the insider confidence against the broader financial metrics and consider whether the company’s recent clinical milestones justify a more aggressive investment thesis.